ARGX-117
Complement-mediated diseases
Phase 1/2Active
Key Facts
About Argenx
argenx is a Dutch-American biotechnology company focused on developing innovative antibody therapies for patients suffering from severe autoimmune diseases and cancer. Founded in 2008, the company has successfully commercialized VYVGART® (efgartigimod) for myasthenia gravis and is advancing multiple programs leveraging its proprietary SIMPLE Antibody™ platform. With operations in the Netherlands, Belgium, and the United States, argenx has established itself as a leader in FcRn antagonist therapies and immunology drug development.
View full company profileOther Complement-mediated diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Pozelimab | Regeneron Pharmaceuticals | Phase 2/3 |
| ANX009 | Annexon | Preclinical |
| ADX-096 | Q32 Bio | Discovery/Preclinical |
| C3d mAb fusions | Q32 Bio | Discovery/Preclinical |
| Complement-targeting nanobodies | Q32 Bio | Discovery/Preclinical |
| RLYB116 | Rallybio | Phase 1 |